Immunotherapy for Inhalant Allergy
Introduction
Introduction
- Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
- Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
- Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
- Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.
Treatment
...reatment
...bbreviations and Definitions of Common TermsHavin...
Table 2. Summary of Guideline Key Act...
...ssessme...
...r Allergen ImmunotherapyClinicians should offer or...
...hould not get Allergen ImmunotherapyClinicians s...
...Who may not get Allergen ImmunotherapyCli...
...a AssessmentClinicians should evaluate the...
...ducation...
...Education regarding SLIT versus SCITClinicia...
...ion regarding Preventive Qualities of Allerge...
...eatmen...
...easonal TherapyClinicians who administer SL...
...electing Clinically Relevant Allergen...
...olysensitized Patients with Limited AllergensC...
...ons and Allergen Immunotherapy Escala...
...Anaphylaxis Identification and ManagementThe...
...During Allergen ImmunotherapyClinicians should av...
...or Allergen ImmunotherapyFor patients wh...
Table 3: Comparison of SCIT and SLIT...
...llergy Organization Subcutaneous Immunother...
...o-Seasonal SLIT Time CourseTime cou...
...hylaxis Diagnostic Criteria Reproduced from...
...Differentiating Between Vasovagal a...
...nagement of AnaphylaxisReproduced from...
...re 4. Flowchart Showing Key Action Stat...